



10th ANNUAL (VIRTUAL) MEETING OF THE LUPUS ACADEMY

# Meeting Book

**Virtual Meeting**  
6th, 9th, 12th and 16 – 18th April, 2021



# Welcome

## Dear Friends and Colleagues,

We are delighted to welcome you to the 10th Annual Meeting of The Lupus Academy<sup>†</sup>, which will enrich your knowledge and help you better manage your patients with lupus.

The Lupus Academy is committed to the development of high-quality education, focused on providing up to date and clinically relevant content through live and online meeting environments. We aspire to support you in your delivery of outstanding patient care and efforts to improve patient outcomes in lupus.

This second Virtual Annual Meeting will take place over several dates in April 2021 and deliver the latest advances in research and clinical practice in lupus and allied diseases. Delegate feedback from previous annual meetings continues to guide us in selecting the finest topics and speakers. This meeting has been approved for *AMA PRA Category 1 Credit*<sup>™</sup>.

The scientific component of this programme, developed by our Steering Committee of 12 international experts in lupus, provides the opportunity for you to engage with clinicians and scientists, share clinical and scientific experience, and further develop your knowledge in this fast-moving therapeutic area.

We sincerely hope that this meeting will provide you with new ideas for your clinical work, enriched enthusiasm for collaborative research, and fruitful discussions with your colleagues.

We look forward to meeting and talking with you online, on the 6th, 12th and 16–18th April 2021.

With kind regards,

**Professor Zahir Amoura**

Lupus Academy co-Chair (2021)

**Professor Richard Furie**

Lupus Academy co-Chair (2021)

**Professor Eloisa Bonfá**

**Professor Bevra Hahn**

**Professor Murray Urowitz**

**Professor Ricard Cervera**

**Professor David Isenberg**

**Professor Ronald van Vollenhoven**

**Professor Thomas Dörner**

**Professor Bernardo Pons-Estel**

**Professor Andrea Doria**

**Professor Sandra Navarra**

<sup>†</sup>The Lupus Academy is a long-term initiative dedicated to improving patient outcomes in SLE through an interactive educational forum dedicated to sharing best clinical practice through the dissemination and discussion of clinical and basic scientific research about SLE and allied diseases.



# Meeting Learning Objectives

The Lupus Academy's 10th Annual Meeting programme will focus on current key issues in lupus clinical practice and is designed to facilitate improved understanding of these issues and their management through both didactic lectures and shared clinical insights through case study workshops. At the end of the programme delegates should be able to:

- Explain best diagnostic approach and novel therapeutic options for the optimal management of patients with lupus
- Describe how drug de-escalation strategies work and how these translate into improved clinical outcomes for patients with SLE
- Discuss the role of complement in SLE and specific manifestations of lupus and allied diseases
- Describe recent developments in novel treatment options and optimizing treatment strategies for the management of SLE
- Demonstrate practical implementation of case-based learning strategies in diagnosis and treatment of cutaneous lupus, lupus nephritis, paediatric SLE, pregnancy and SLE, and NPSLE
- Demonstrate understanding of the scientific and clinical implications (including COVID-19) of new research that is transforming treatment for patients with SLE
- Explain the role of interferon and use of interferon inhibition in the future management of SLE
- Describe diagnostic challenges in different manifestations including antiphospholipid syndrome and lupus nephritis
- Discuss clinical practice challenges associated with CAPS, refractory cutaneous lupus, osteonecrosis and alveolar haemorrhage

Abstracts of the presentations are published in the official journal of the 10th Annual Meeting:



## Continuing Medical Education



This meeting has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Learning and the Lupus Academy. Siyemi Learning is accredited by the ACCME to provide continuing medical education for physicians.

Siyemi Learning designates this live activity for a maximum of 18 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information on how to claim CME credits can be found on the meeting website. The CME credits are recognised across Europe and globally. Please check with your local authority to confirm its validity for your purposes.

## Disclosures

Financial disclosures of the speakers can be found with their biography in this book.

Neither the Lupus Academy planning staff, Julian Ball, Nicole Elzebroek, Eugene Pozniak, nor staff at Siyemi Learning, have any relevant financial relationships to disclose.

Further information about Lupus Academy, partners and sponsors can be found on Page 32 and 33 of this book.



# Contents

<b>Programme .....</b>	<b>4</b>
<b>Biographies .....</b>	<b>12</b>
<b>Notes .....</b>	<b>34</b>



# Programme

## Lupus Academy 10th Annual Meeting: Early Sessions (Online)

### SESSION 1: SLE TREATMENT DILEMMAS

**Tuesday 6th April 2021: 14:00–15:30 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 9:30 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 21:30 hours

<b>Moderators: Andrea Doria (Italy), David Isenberg (UK)</b>	
Should we vaccinate all SLE patients against papillomavirus and herpes zoster? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Sarfaraz Hasni (USA)</i>
Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Murray Urowitz (Canada)</i>
Low dose aspirin in aPL-positive patients: Are we treating the patient or the doctor? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Denis Wahl (France)</i>

### SESSION 2: THE ROLE OF INTERFERONS IN SLE

**Friday 9th April 2021: 14:00–15:30 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 9:30 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 21:30 hours

<b>Moderators: Zahir Amoura (France), Thomas Dörner (Germany)</b>	
Biology of interferons <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Mary Crow (USA)</i>
How interferonopathies inform SLE pathogenesis <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Yanick Crow (UK)</i>
Interferon inhibition and the future management of SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Eric Morand (Australia)</i>

### SESSION 3: LESSONS LEARNED FROM OTHER DISEASES

**Monday 12th April 2021: 14:00–16:00 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 10:00 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 22:00 hours

<b>Moderators: Eloisa Bonfá (Brazil), Ronald van Vollenhoven (Netherlands)</b>	
Lessons from transplantation: Multitargeted therapy for proliferative lupus nephritis <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Daniel Tak Mao Chan (Hong Kong)</i>
Lessons from ITP: Treatment of refractory thrombocytopenia <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Sacha Zeerleder (Netherlands)</i>
Lessons from scleroderma: Treatment of interstitial lung disease in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Oliver Distler (Switzerland)</i>
Lessons from RA: RA drug development has advanced at a more rapid pace than SLE: What can we learn from our colleagues? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Ronald van Vollenhoven (Netherlands)</i>

## Friday 16th April 2021

### OPENING SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:00–15:15 hours

EDT (UTC-4 New York, Montreal) 7:00 AM – 9:15 AM

CST (UTC+8 Beijing, Manila, Perth) 19:00 – 21:15 hours

<b>Opening</b>	<i>Zahir Amoura (France), Richard Furie (USA)</i>
----------------	---

<b>Keynote</b>	
<b>Moderator: Richard Furie (USA)</b>	
Kidney biopsies in SLE: Too few or too many? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Hans-Joachim Anders (Germany)</i>

<b>Debate: In With the New, Out With Old? Should All Patients with Lupus Nephritis Receive New Generation Therapies in Addition to Established Standard of Care?</b>	
<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>	
The matter of the debate (10 mins)	<i>Ronald van Vollenhoven (Netherlands)</i>
All lupus nephritis patients should be initially managed with <b>both established standard therapies and the new generation drugs</b> (20 mins + 10 mins rebuttal)	<i>Onno Teng (Netherlands)</i>
All lupus nephritis patients should be initially managed with <b>established standard therapies alone</b> (20 mins + 10 mins rebuttal)	<i>Dimitrios Boumpas (Greece)</i>
<b>Voting, Q&amp;A and Discussion (20 Mins)</b>	<i>All</i>

### PLENARY I: NOVEL STRATEGIES FOR OPTIMIZING OUTCOMES IN SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours

EDT (UTC-4 New York, Montreal) 9:30 AM – 11:30 AM

CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:30 hours

<b>Moderators: Sandra Navarra (Philippines)</b>	
Preventing damage and reducing mortality in lupus. How are we doing? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Murray Urowitz (Canada)</i>
Strategies for minimizing corticosteroid exposure in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Zahir Amoura (France)</i>
Targeting remission and low disease activity in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Andrea Doria (Italy)</i>
Lupus treatment in the next decade: The next decade is upon us <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Richard Furie (USA)</i>

# Programme

## OPENING SESSION (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 18:00–20:15 hours

EDT (UTC-4 New York, Montreal) 12:00 PM – 2:15 PM

CST (UTC+8 Beijing, Manila, Perth) 00:00 – 02:15 hours

<b>Opening</b>	<i>Zahir Amoura (France), Richard Furie (USA)</i>
<b>Keynote</b>	
<b>Moderator: Richard Furie (USA)</b>	
Kidney biopsies in SLE: Too few or too many?	<i>Hans-Joachim Anders (Germany)</i>
<b>Recorded Q&amp;A and Discussion (15 Mins)</b>	
<b>Debate: In With the New, Out With Old? Should All Patients with Lupus Nephritis Receive New Generation Therapies in Addition to Established Standard of Care?</b>	
<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>	
The matter of the debate (10 mins)	<i>Ronald van Vollenhoven (Netherlands)</i>
All lupus nephritis patients should be initially managed with <b>both established standard therapies and the new generation drugs</b> (20 mins + 10 mins rebuttal)	<i>Onno Teng (Netherlands)</i>
All lupus nephritis patients should be initially managed with <b>established standard therapies alone</b> (20 mins + 10 mins rebuttal)	<i>Dimitrios Boumpas (Greece)</i>
<b>Recorded Voting, Q&amp;A and Discussion (20 Mins)</b>	<i>All</i>

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.



**Saturday 17th April 2021**

## PLENARY I: NOVEL STRATEGIES FOR OPTIMIZING OUTCOMES IN SLE (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 07:00–09:00 hours

EDT (UTC-4 New York, Montreal) 1:00 AM – 3:00 AM

CST (UTC+8 Beijing, Manila, Perth) 13:00 – 15:00 hours

<b>Moderators: Sandra Navarra (Philippines)</b>	
Preventing damage and reducing mortality in lupus. How are we doing? <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Murray Urowitz (Canada)</i>
Strategies for minimizing corticosteroid exposure in SLE <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Zahir Amoura (France)</i>
Targeting remission and low disease activity in SLE <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Andrea Doria (Italy)</i>
Lupus treatment in the next decade: The next decade is upon us <b>Recorded Q&amp;A and Discussion (15 Mins)</b>	<i>Richard Furie (USA)</i>

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

## CASE STUDY INTERACTIVE WORKSHOPS

CET (UTC+2 Paris, Amsterdam, Berlin) 09:00–10:30 hours

EDT (UTC-4 New York, Montreal) 3:00 AM – 4:30 AM

CST (UTC+8 Beijing, Manila, Perth) 15:00 – 16:30 hours

<b>Moderator/Facilitator: Andrea Doria (Italy)</b>	
Cutaneous lupus	<i>Bernardo Pons-Estel (Argentina), Annegret Kuhn (Germany)</i>
<b>Moderator/Facilitator: Sandra Navarra (Philippines)</b>	
Lupus nephritis	<i>Liz Lightstone (UK), Sandra Navarra (Philippines)</i>
<b>Moderator/Facilitator: David Isenberg (UK)</b>	
Paediatric SLE	<i>Alexandre Belot (France), Rolando Cimaz (Italy)</i>
<b>Moderator/Facilitator: Ricard Cervera (Spain)</b>	
Neuropsychiatric SLE	<i>Ricard Cervera (Spain), Thomas Huizinga (NL)</i>
<b>Moderator/Facilitator: Eloisa Bonfá (Brazil)</b>	
Reproductive health in SLE	<i>Lisa Sammaritano (USA), Rebecca Fischer-Betz (Germany)</i>

## HOT TOPICS: THE ROLE OF COMPLEMENT IN SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 11:00–13:00

EDT (UTC-4 New York, Montreal) 5:00 AM – 7:00 AM

CST (UTC+8 Beijing, Manila, Perth) 17:00 – 19:00 hours

<b>Moderators: Thomas Dörner (Germany), David Isenberg (UK)</b>	
Complement in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	<i>John Atkinson (USA)</i>
The role of complement and complement inhibition in APS pregnancy <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Jane Salmon (USA)</i>
The interface of the complement and coagulation pathways <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Edward Conway (Canada)</i>
Lessons learned from complement inhibition in ANCA vasculitis <b>Q&amp;A and Discussion (15 Mins)</b>	<i>David Jayne (UK)</i>

# Programme

## PRIME TIME SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:30–15:30 hours

EDT (UTC-4 New York, Montreal) 7:30 AM – 09:30 AM

CST (UTC+8 Beijing, Manila, Perth) 19:30 – 21:30 hours

### Hot Topics: Highlighting Accomplishments in Lupus Research

**Moderators: Murray Urowitz (Canada), David Isenberg (UK)**

Translational insights into the pathogenesis transforming SLE treatment <b>Q&amp;A and Discussion (15 Mins)</b>	Thomas Dörner (Germany)
--	-------------------------

Clinical science highlights that are transforming treatment <b>Q&amp;A and Discussion (15 Mins)</b>	Bevra Hahn (USA)
--	------------------

### Thieves' Market

**Moderators: Richard Furie (USA), Eloisa Bonfá (Brazil)**

Case in practice: Neither arms NOR legs were feeling well <b>Q&amp;A (10 Mins)</b>	Eduardo Dourado (Portugal)
---	----------------------------

Case in practice: Born together, best friends together <b>Q&amp;A (10 Mins)</b>	Rinat Raupov (Russia)
--	-----------------------

Case in practice: A short hi-storiform of time in clinic <b>Q&amp;A (10 Mins)</b>	Saskia Rowson (Australia)
--	---------------------------

### Voting and Panel Discussion

## CASE STUDY INTERACTIVE WORKSHOPS

CET (UTC+2 Paris, Amsterdam, Berlin) 16:00–17:30 hours

EDT (UTC-4 New York, Montreal) 10:00 AM – 11:30 PM

CST (UTC+8 Beijing, Manila, Perth) 22:00 – 23:30 hours

**Moderator/Facilitator: Andrea Doria (Italy)**

Cutaneous lupus	Bernardo Pons-Estel (Argentina), Annegret Kuhn (Germany)
-----------------	--

**Moderator/Facilitator: Sandra Navarra (Philippines)**

Lupus nephritis	Liz Lightstone (UK), Sandra Navarra (Philippines)
-----------------	---

**Moderator/Facilitator: David Isenberg (UK)**

Paediatric SLE	Alexandre Belot (France), Rolando Cimaz (Italy)
----------------	---

**Moderator/Facilitator: Murray Urowitz (Canada)**

Neuropsychiatric SLE	Ricard Cervera (Spain), Thomas Huizinga (NL)
----------------------	--

**Moderator/Facilitator: Eloisa Bonfá (Brazil)**

Reproductive health in SLE	Lisa Sammaritano (USA), Rebecca Fischer-Betz (Germany)
----------------------------	--

### Close

## HOT TOPICS: THE ROLE OF COMPLEMENT IN SLE (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 18:00–20:00

EDT (UTC-4 New York, Montreal) 12:00 PM – 2:00 PM

CST (UTC+8 Beijing, Manila, Perth) 00:00 – 02:00 hours

**Moderators: Thomas Dörner (Germany), David Isenberg (UK)**

Complement in SLE <b>Q&amp;A and Discussion (15 Mins)</b>	John Atkinson (USA)
--	---------------------

The role of complement and complement inhibition in APS pregnancy <b>Q&amp;A and Discussion (15 Mins)</b>	Jane Salmon (USA)
--	-------------------

The interface of the complement and coagulation pathways <b>Q&amp;A and Discussion (15 Mins)</b>	Edward Conway (Canada)
---	------------------------

Lessons learned from complement inhibition in ANCA vasculitis <b>Q&amp;A and Discussion (15 Mins)</b>	David Jayne (UK)
--	------------------

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

## Sunday 18th April 2021

### PLENARY II: TREATMENT CHALLENGES

CET (UTC+2 Paris, Amsterdam, Berlin) 09:00–11:00 hours

EDT (UTC-4 New York, Montreal) 03:00 AM – 5:00 AM

CST (UTC+8 Beijing, Manila, Perth) 15:00 – 17:00 hours

<b>Moderators: Zahir Amoura (France)</b>	
Treatment of CAPS: Which drugs and in which order? <b>Q&amp;A and Discussion (15 Mins)</b>	Marc Pineton de Chambrun (France)
Refractory cutaneous lupus: Use of thalidomide or lenalidomide for refractory lupus skin disease <b>Q&amp;A and Discussion (15 Mins)</b>	François Chasset (France)
Osteonecrosis: Prevention and treatment <b>Q&amp;A and Discussion (15 Mins)</b>	Bernardo Pons Estel (Argentina)
Alveolar hemorrhage <b>Q&amp;A and Discussion (15 Mins)</b>	Ricard Cervera (Spain)

### POSTER SESSION\*: PRESENTATIONS

CET (UTC+2) Paris, Amsterdam, Berlin) 11:30–12:30 hours

EDT (UTC-4 New York, Montreal) 05:30 AM – 06:30 AM

CST (UTC+8 Beijing, Manila, Perth) 17:30 – 18:30 hours

<b>Moderators: Andrea Doria (Italy), Ronald van Vollenhoven (Netherlands)</b>	
Incorporation of Banff classification in lupus histopathology assessment emphasizes the importance of tubulointerstitial changes <b>Q&amp;A (5 Mins)</b>	Peter Korsten (Germany)
ISG15 deficiency underlie monogenic lupus with inflammatory myositis <b>Q&amp;A (5 Mins)</b>	Lujayn Akbar (Saudi Arabia)
Immunophenotype of systemic lupus erythematosus and Sjögren's syndrome patients identified two endotypes with potential therapeutic implications <b>Q&amp;A (5 Mins)</b>	Lucia Martin-Gutierrez (UK)
Comparison of different definitions of remission in children with lupus nephritis <b>Q&amp;A (5 Mins)</b>	Chiara De Mutis (Italy)
Multi-omic analysis identifies dyslipidaemia in juvenile-SLE patients associated with disease activity, inflammation and atherosclerosis <b>Q&amp;A (5 Mins)</b>	George Robinson (UK)

\*More Posters Available Online

### MEETING HIGHLIGHTS

CET (UTC+2) Paris, Amsterdam, Berlin) 13:00–14:00 hours

EDT (UTC-4 New York, Montreal) 07:00 AM – 08:00 AM

CST (UTC+8 Beijing, Manila, Perth) 19:00 – 20:00 hours

<b>Moderators: Zahir Amoura (France), Richard Furie (USA)</b>	
Meeting Highlights	Eloisa Bonfá (Brazil), David Isenberg (UK), Richard Furie (USA), Zahir Amoura (France)
Questions and Answers (Live)	Steering Committee
<b>Close</b>	Zahir Amoura (France), Richard Furie (USA)



# Programme

## MEET THE EDITOR

CET (UTC+2) Paris, Amsterdam, Berlin) 14:15 – 15:00 hours

EDT (UTC-4 New York, Montreal) 8:15 AM – 9:00 AM

CST (UTC+8 Beijing, Manila, Perth) 20:15 – 21:00 hours

<b>Moderator: Ronald van Vollenhoven (Netherlands)</b>	
Introduction: What is happening in the world of publishing?	<i>Ronald van Vollenhoven (Netherlands)</i>
Workshop: How do I get my manuscript published—in the best possible journal?	
Tips for reviewers: make it work for the authors and yourself	

## PLENARY II: TREATMENT CHALLENGES (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours

EDT (UTC-4 New York, Montreal) 9:30 AM – 11:30 AM

CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:30 hours

<b>Moderators: Zahir Amoura (France)</b>	
Treatment of CAPS: Which drugs and in which order? <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Marc Pineton de Chambrun (France)</i>
Refractory cutaneous lupus: Use of thalidomide or lenalidomide for refractory lupus skin disease <b>Q&amp;A and Discussion (15 Mins)</b>	<i>François Chasset (France)</i>
Osteonecrosis: Prevention and treatment <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Bernardo Pons Estel (Argentina)</i>
Alveolar hemorrhage <b>Q&amp;A and Discussion (15 Mins)</b>	<i>Ricard Cervera (Spain)</i>

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.





# Biographies



*Professor Amoura is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

## Financial Disclosures

None

## Professor Zahir Amoura, MD, MSc

**French National Reference Center for SLE and APS, Pitié-Salpêtrière Hospital, Paris, France**

Zahir Amoura is Professor of Internal Medicine at the French National Reference Center for Systemic Lupus Erythematosus at Pitié-Salpêtrière Hospital, a role that he has held since 2003. In 2009, Professor Amoura became Head of the Department of Internal Medicine 2 in the same institution. Professor Amoura completed his Paris Hospital Medical Internship in 1988, and obtained a Master's degree in Immunopharmacology in 1989. He was subsequently awarded his MD (silver medal) in 1993 and his qualifying certification in internal medicine in 1994. Professor Amoura joined the Department of Internal Medicine at Pitié-Salpêtrière Hospital in 1995 as a Senior Lecturer and Senior Practitioner. Professor Amoura has published 563 peer-reviewed papers, of which 251 focused on the immunopathological features of lupus.



## Financial Disclosures

**Consultant/Advisor:** GSK;  
Jansen; Kezar; Novartis

## Professor Hans-Joachim Anders, MD

**University of Munich, Germany**

Hans-Joachim Anders is Professor of Nephrology and Head of the Renal Division at the inner city campus of the LMU University Hospital, Munich, Germany.


Professor Anders received his medical degree from the Universities of Göttingen and Würzburg and his qualification in Nephrology and Rheumatology from the University of Munich. He is the secretary coordinator of the scientific advisory board of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA), a board member of the Immunonephrology Working Group of ERA-EDTA, a member of the Western-European Regional Board of the International Society of Nephrology (ISN) and a member of the Executive Board of the Lupus Nephritis Trials Network. He is also a member of EUROSLE.

Professor Anders has organized numerous regional and international conferences including the 2016 ISN Nexus Meeting, Translational Immunology in Kidney Disease in Berlin together with Professor Brad Rovin and Professor David Jayne. He was a member of the group preparing the 2019 Update of the "Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis".

Professor Anders serves as an Editor on Editorial Boards of several international journals and is currently associate editor at *The Journal of the American Society of Nephrology* and at *Nephrology Dialysis and Transplantation*. He is also an advisor for *Nature Reviews Nephrology*.

He has authored over 350 PubMed publications, mostly on innate immune mechanisms in autoimmunity and kidney inflammation, many of which about the experimental pathophysiology and clinical aspects of lupus and lupus nephritis. He recently authored a *Nature Reviews Disease Primer* about lupus nephritis. He frequently speaks about how pathophysiology connects to clinical unmet needs and novel treatment approaches at international meetings.

Professor Anders has long-standing experience of the clinical management of patients with kidney involvement due to systemic disorders such as lupus at LMU.



**Professor John Atkinson, MD**  
Washington University School of Medicine, St. Louis, USA

John Atkinson is Samuel Grant Professor of Medicine and Professor of Molecular Microbiology at Washington University School of Medicine, St. Louis USA.

Professor Atkinson has nearly 50 years of research experience in innate immunity, especially relative to investigating the workings of the complement system. He received his BA and MD degrees from the University of Kansas. His training in internal medicine was at the Massachusetts General Hospital and the National Institutes of Health and his postdoctoral research training was at the National Institutes of Health and at Washington University. Between 1976 and 1992, he directed Washington University's Division of Rheumatology and was an investigator of the Howard Hughes Medical Institute from 1976 to 1992. During this time, he trained nearly 100 pre-doctoral students and post-doctoral fellows, many of whom have gone on to independent research positions and distinguished careers in academia, government and the biotechnology and pharmaceutical industries.

Like many physician scientists of his "vintage", he started out as an immunologist/cell biologist and then evolved to employ protein chemistry, molecular biology and, more recently, modern genetics to learn more about how the complement system functions in human disease. Since the early 1970s, he has developed a strong interest in the role of complement activation in lupus pathogenesis and in complement deficiency predisposing to lupus.

**Financial Disclosures**  
None



**Professor Alexandre Belot, MD, PhD**  
University of Lyon, France

Alexandre Belot is Professor of Pediatrics and Head of the National Reference center for rare Rheumatic and AutoImmune diseases in childrEn (RAISE) in Lyon, France. He is also co-Chair of the national network on rare autoimmune and autoinflammatory diseases FAI2R ([www.fai2r.org](http://www.fai2r.org)).

Professor Belot is a clinical scientist and has a research group among the Dr Walzer laboratory in the Centre International de Recherche en Infectiologie in Lyon, working on rare monogenic inflammatory diseases. His research focuses on juvenile systemic lupus erythematosus (jSLE), with a specific interest on monogenic lupus. He is conducting whole exome or whole genome sequencing strategies to discover new pathways involved in lupus and tolerance defect. Professor Belot also hosts the national biobank for jSLE in Lyon. He is co-Chair of the pediatric rheumatology diploma in France and contributes to numerous educational sessions on pathogenesis of jSLE for scientists and clinicians every year. He has authored over 150 peer-reviewed publications, and is Associate Editor of *Frontiers in Immunology* (autoimmune and autoinflammatory disorders section).

**Financial Disclosures**  
None

# Biographies



*Professor Bonfá is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

**Financial Disclosures**  
None

**Professor Eloisa Bonfá, MD, PhD**  
**University of São Paulo Medical School, São Paulo, Brazil**

Eloisa Bonfá is the Physician-in-Chief of the Rheumatology Division of Hospital das Clinicas HCFMUSP, São Paulo, which is the largest tertiary referral centre for autoimmune rheumatic disorders of Latin America. She is now in her third term elected Clinical Director of Hospital das Clinicas HCFMUSP, University of São Paulo.

Professor Bonfá's main clinical and research interest is systemic lupus erythematosus and autoimmunity, with relevant contribution in the field of autoantibodies and original contribution regarding the association of anti-ribosomal P antibodies with psychiatric manifestation of lupus and the first "in vitro" demonstration of the arrhythmogenic potential of purified Ro/SSA antibodies. She also has described the association of anti-ribosomal P antibodies and lupus membranous nephritis. She has published several papers on vaccine immunogenicity and safety in autoimmune disorders. More recently, she has been dedicated to monitoring hydroxychloroquine blood levels in lupus patients.

Having graduated at the University of São Paulo Medical School, Brazil, Professor Bonfá undertook specialist training in Rheumatology in the same University followed by a 4 year rheumatology research fellowship at the Hospital for Special Surgery, New York, USA, under the supervision of Professor Keith Elkon. She has published more than 300 original papers indexed in PubMed and several book chapters.



**Financial Disclosures**  
None

**Professor Dimitrios Boumpas, MD, FACP**  
**National and Kapodistrian University of Athens, Greece**

Dimitrios T. Boumpas, graduated from the Medical School at the University of Ioannina in 1983. Following a fellowship in Molecular Immunology at National Institutes of Health (NIH), Bethesda MD, he trained in Internal Medicine at Georgetown University, Washington DC and in Rheumatology-Clinical Immunology at ARB, NIAMS, NIH. Upon the completion of his training, he was appointed an Investigator at ARB, NIAMS, NIH where he served as Deputy and Acting Clinical Director.

In 1999, he repatriated to the University of Crete to lead the Departments of Rheumatology, Clinical Immunology and Allergy, and Internal Medicine. While in Crete, Professor Boumpas directed the Graduate Program on the Molecular Basis of Human Diseases. In 2012 he joined the Medical School, University of Athens, where he currently serves as the Chairman of the Fourth Department of Medicine at Attikon University Hospital. He is also an affiliate member of the Institute for Biomedical Research of the Academy of Athens.

Professor Boumpas' primary clinical and research interests are in the areas of human autoimmunity with emphasis on systemic lupus erythematosus (SLE) and inflammatory arthritis. His work on the treatment of lupus nephritis has shaped immunosuppressive therapy internationally. He is also a leader in the transcriptomic analysis in human systemic autoimmunity. He has published over 328 peer-reviewed scientific papers and 50 book chapters. His research was funded by both National (ΕΠΕΑΕΚ II, Πυθαγόρας I, II, Ηράκλειτος, Θαλής, Αριστεία) και European Union research funds (AUTOCURE FP-6; BTCURE, IMI, HORIZON 2020, ERC Advanced Grants).

Professor Boumpas is Member of the Academia Europaea and President of the Athens Medical Society. He is also past-Chair of the Training and Education Committee for the European League against Rheumatism; Chair of European Task force on SLE that develops guidelines for the management and coordinates clinical trials and research on SLE; Vice Chair ERC Synergy grants; and Associate Editor of Annals of Rheumatic Diseases. He is past-Chair of the European Research Council Panel for Advanced Grants on Diagnostics Tools, Therapies and Public Health (LS-7) and has served on the EU ESRF Committee for Translational Research Infrastructures.



**Professor Ricard Cervera, MD, PhD, FRCP**  
Hospital Clinic, Barcelona, Catalonia, Spain

Ricard Cervera is co-Founder and Head of the Department of Autoimmune Diseases at Hospital Clinic, Barcelona. He is also leader of the Research Team on Systemic Autoimmune Diseases at the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and Professor at the University of Barcelona where he coordinates the Masters Course on Autoimmune Diseases and serves as Vice-Dean of Academic Affairs and International Relations at its Faculty of Medicine and Health Sciences. He qualified in medicine in 1983 from the University of Barcelona and received his PhD in 1988 for his thesis on anticardiolipin antibodies. He spent 2 years at the Lupus Research Unit at The Rayne Institute, St Thomas' Hospital, London, UK.

Professor Cervera is an Associate Editor of the journal Lupus Science & Medicine and is on the Editorial Boards of 20 medical journals. He is Founder and Member of the Board of the European Lupus Society and past-coordinator of the European Working Party on Systemic Lupus Erythematosus (Euro-Lupus Group) (1991–2008) and of the European Forum on Antiphospholipid Antibodies (2009–2017). He is Chairman of the Medical Advisory Board of the Catalan Association of Lupus Patients and Medical Advisor to Lupus Europe. He chaired the 6th, 8th and 11th International Congresses on Autoimmunity, the 1st, 2nd and 5th Latin-American Congresses on Autoimmunity, the 5th Meeting of the European Forum on Antiphospholipid Antibodies and the 8th European Lupus Congress.

Professor Cervera's research interests include clinical and epidemiological aspects of systemic autoimmune diseases, particularly SLE and antiphospholipid syndrome, with special focus on its 'catastrophic' variant. He has presented over 300 invited lectures and published more than 800 scientific papers (H-Index, 79), including original articles in the New England Journal of Medicine, The Lancet, Annals of Rheumatic Diseases, Arthritis & Rheumatism, American Journal of Medicine and Medicine (Baltimore). He is co-Editor of 25 books, including 'The Antiphospholipid Syndrome', 'Vascular Manifestations of Systemic Autoimmune Diseases' and 'Diagnostic Criteria in Autoimmune Diseases'.

*Professor Cervera is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

**Financial Disclosures**

None



**Professor Tak Mao Daniel Chan, FRCP, FHKCP, MBBS, MD, DSc**  
The University of Hong Kong, China

Daniel Tak Mao Chan, FRCP, FHKCP, obtained his MBBS, MD, and DSc from the University of Hong Kong (HKU). He became Personal Chair Professor at HKU in 2005, Yu Professor in Nephrology in 2008, and Yu Chiu Kwong Professor in Medicine in 2011. He has been Chief of Nephrology since 2010. He has served as Associate Dean and Senate member at HKU, President of Asian Pacific Society of Nephrology (APSN), and ISN Council member. Since 2016 he is Vice-President and Chairman of the Education and Accreditation Committee of the Hong Kong College of Physicians.

His research focuses on lupus nephritis and viral hepatitis in patients with kidney diseases. His work has helped establish mycophenolate as standard-of-care for lupus nephritis, and preventive antiviral therapy as standard-of-care for kidney transplant recipients with hepatitis B, both contributing to significantly improved patient outcomes. Translational studies from his laboratory have increased the understanding of pathogenic mechanisms in renal inflammation and fibrosis. His publications have appeared in *N Engl J Med*, *Kidney Int*, *J Am Soc Nephrol*, *Arthritis Rheum*, *Nat Rev Nephrol*, *Hepatology*, and *UpToDate*. He received the APSN Kenzo Oshima Award in 2014 in recognition of his contributions to Nephrology in the Asian Pacific region.

**Financial Disclosures**

Grants/Research: Astellas



# Biographies



**Dr Francois Chasset, MD, PhD**  
Sorbonne Université, Paris, France

François Chasset is Assistant Professor in the Department of Dermatology of Tenon Hospital in Paris, France.

He received his medical degree and qualification in dermatology from the University of Paris in 2016 and a PhD focusing on the development of biomarkers in systemic lupus in 2020. He became Assistant Professor in 2020.

Dr Chasset is involved in the management of cutaneous lupus as well as cutaneous manifestations of systemic lupus since 2016 in a tertiary referral dermatology centre. He participated in the last international meeting on CLE (ICCLE, Orlando 2018).

He has authored 36 iSi publications on systemic and cutaneous lupus erythematosus.

## Financial Disclosures

Consultant/Advisor: Celgene;  
GSK; Principabio



**Professor Rolando Cimaz, MD, PhD**  
University of Milano, Italy

Rolando Cimaz is a Full Professor of Rheumatology at the University of Milano, Italy, and Head of the Pediatric Rheumatology Unit at the Gaetano Pini Institute, also in Milano.

He graduated from Milan University in Italy in 1987, is a specialist in Pediatrics and in Rheumatology, and did his Fellowship in Pediatric Rheumatology in Dallas, Texas. He was Maitre de Conférences des Universités at Université Claude Bernard-Lyon I in Lyon, France from 2005 to 2007, and an Associate Professor of Pediatrics at the University of Florence from 2007 to 2019.

Professor Cimaz's main interest is pediatric rheumatology, and he has special expertise and scientific interest in osteoporosis, antiphospholipid antibodies, Kawasaki disease, synovial T cells and neonatal lupus. He has been in the Council of the Pediatric Rheumatology European Society from 1999 to 2005 (treasurer) and from 2014 to 2015 (Research Chair). He is a member of the Italian, French, and European Societies of Pediatrics and Rheumatology and the American College of Rheumatology.

Professor Cimaz is an Editorial board member of *Lupus*, *Frontiers in Pediatrics*, *Pediatric Rheumatology*. He has co-authored more than 400 peer reviewed articles (PubMed) and more than 20 book chapters, all in the field of pediatric rheumatology. His current H-index (Google Scholar) is 68.

## Financial Disclosures

None





**Professor Edward Conway, MD, PhD, MBA**  
University of British Columbia, Vancouver, Canada

Edward Conway is Professor of Medicine in the Division of Hematology-Oncology and the Director of the Centre for Blood Research (CBR) at the University of British Columbia in Vancouver.

He was born and educated in Toronto, receiving degrees in Engineering and Medicine from the University of Toronto. After further training in Hematology-Oncology at Harvard and MIT in Boston, he returned to Toronto as a physician-scientist and hematologist, establishing a research group in vascular biology.

In 1995, Professor Conway was recruited to the University of Leuven in Belgium as a Senior Scientist, where he joined the faculty of the Vesalius Research Center. In addition to leading a research group focused on delineating mechanisms underlying vascular thrombotic diseases, he coordinated collaborations with industry and organized graduate educational programmes.

Professor Conway returned to Canada in 2009 as a Professor of Medicine in the Division of Hematology-Oncology and the Director of the CBR at the University of British Columbia in Vancouver. His research is aimed at characterizing the interplay between the vascular endothelium, coagulation, complement and inflammation using a range of technologies, from bench to bedside. He is supported by grants from the Heart and Stroke Foundation of Canada, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, Canada Foundation for Innovation, CanVECTOR, MITACs, and the Canada Research Chairs programme.

**Financial Disclosures**  
None



**Professor Mary Crow, MD**  
Weill Cornell Medical College, New York, USA

Mary Crow is Physician-in-Chief Emeritus at Hospital for Special Surgery, Professor of Medicine at Weill Cornell Medical College, and Professor of Immunology in its Graduate School of Medical Sciences. Professor Crow is also Senior Scientist, Co-Director of the Mary Kirkland Center for Lupus Research, and Director of the Autoimmunity and Inflammation Program at Hospital for Special Surgery's Research Institute where she holds the Benjamin M. Rosen Chair in Immunology and Inflammation Research.

Professor Crow received her MD from Cornell University Medical College, Internal Medicine and Rheumatology subspecialty training at New York Hospital and Hospital for Special Surgery, and post-doctoral research training at Rockefeller University. Her research has focused on the induction and regulation of human autoimmune diseases, and she continues to investigate the cellular and cytokine mediators of immune system activation and inflammation in those disorders.

Professor Crow's leadership roles have included President of the American College of Rheumatology, President of the Henry Kunkel Society, and co-Chair of the Scientific Advisory Board of the Lupus Research Alliance. In 2017 Professor Crow was named an honorary member of the European League Against Rheumatism, in 2018 she received the Presidential Gold Medal from the American College of Rheumatology in recognition of outstanding contributions to rheumatology over an entire career. In 2019 she was recognized as a "Notable Woman in Healthcare" by Crain's New York Business.

**Financial Disclosures**

**Grants/Research:** *Gilead Sciences*

**Consultant/Advisor:**  
*AstraZeneca; BMS; GSK; Lilly; Shannan Pharmaceuticals*

**Stock Holder:** *Amgen; JnJ; Praxis; Regeneron; 10x Genomics*

# Biographies



**Professor Yanick Crow, MD, PhD**

**Institute of Genetics and Molecular Medicine, Edinburgh, UK**

Yanick Crow is a clinical scientist and Fellow of the Academy of Medical Sciences, working between the Medical Research Council (MRC) Institute of Genetics and Molecular Medicine, Edinburgh, UK, and the Institut Imagine, Paris, France.

Professor Crow has an interest in monogenic disorders associated with an up-regulation of type I interferons – a set of inborn errors of immunity resulting from abnormal sensing, inappropriate stimulation, or defective negative regulation of the type I interferon system. Understanding these so-called type I interferonopathies has the potential to provide insights into immunological homeostasis, mechanisms of self / non-self discrimination and viral immunity.

## Financial Disclosures

None



**Professor Oliver Distler, MD**

**University of Zürich, Switzerland**

Oliver Distler is Professor of Rheumatology and Chairman of the Department of Rheumatology at the University of Zürich. He also leads the Center of Experimental Rheumatology of the University of Zürich. This Department of Rheumatology has been awarded a EULAR Center of Excellence due to its scientific achievements.

Professor Dr. Distler has authored over 300 primary research papers, over 21,000 citations and an H-Factor of 73. He is among the top three cited researchers worldwide in the field of systemic sclerosis. His research activities span from a preclinical programme, focusing on the characterisation of key molecules and intracellular signalling cascades driving the disease process, to a translational and clinical programme, with emphasis on precision medicine and Phase 2/3 clinical trial design.

## Financial Disclosures

**Grants/Research:** *Kymera*

*Therapeutics; Mitsubishi Tanabe*

**Consultant/Advisor:** *Abbvie;*

*Accelaron; Amgen; AnaMar;*

*Anxx; Baecon; Blade; Bayer;*

*Boehringer Ingelheim;*

*ChemomAb; Corbus; CSL*

*Behring; Galapagos NV;*

*Glenmark; GSK; Horizon*

*(Curzion); Inventiva; iQvia;*

*Italfarmaco; Kymera; Medac;*

*Medscape; Mitsubishi Tanabe;*

*MSD; Novartis; Pfizer; Roche;*

*Roivant; Sanofi; Serodapharm;*

*Topadur and UCB*

**Speakers' Bureau:** *Bayer;*

*Boehringer Ingelheim; iQone;*

*Medscape; Novartis; Roche;*

*MSD; Novartis; Pfizer; Lilly;*

*Roche*



## **Professor Andrea Doria, MD** University of Padova, Italy

Andrea Doria is Professor of Rheumatology and Head of the Rheumatology Unit and Unit of Connective Tissue Disease and Rare Rheumatic Diseases, Department of Medicine, University of Padua, Italy. He is also Director of Postgraduate School on Rheumatology of University of Padua.

Professor Doria received his medical degree and qualification in Rheumatology from the University of Padua. He was Council member of the Italian College of Rheumatology (CRO) between 1999 and 2005 and a Council member of the Italian Society of Rheumatology (SIR) from 2007 to 2010 and from 2013 to 2015 and from 2018 to 2020. In 2016 he founded the European Lupus Society (SLEuro) and was the first President of the Executive Committee.

Professor Doria has organised over ten international conferences on autoimmunity and was involved as “expert” in the European League Against Rheumatism (EULAR) Standing Committee for the development of clinical and therapeutic recommendations. In 2016 he founded the European Lupus Society (SLEuro) and was the first President of the Executive Committee. He was the Chair of the 10th European Lupus Meeting, held in Venice (Italy) 5–8th October 2016, and he will be the Chair of the 14th International Congress on Systemic Lupus Erythematosus which will be held in Venice (Italy) from 6th to 9th October 2021.

Professor Doria is on the Editorial Boards of several rheumatology and immunology journals, including *Lupus*, *Autoimmunity*, *Clinical and Experimental Rheumatology*, *Autoimmunity Reviews*, *Journal of Autoimmunity*, *Experimental Biology and Medicine*, *Rheumatology Reports*, *Journal Autoimmunity Highlights* and *Reumatismo* (the official Journal of Italian Society of Rheumatology).

He has authored over 400 ISI publications on SLE and other connective tissue diseases. These include clinical studies describing new manifestations or subgroups of autoimmune disorders, prognostic risk factors, diagnostic tests and therapeutic interventions, as well as immunochemical studies that evaluate autoantibodies, epitopes and complementary epitopes of autoantigens. In addition, he has authored and co-authored three books.

Professor Doria has long-standing experience of the clinical management of patients with connective tissue diseases. The unit in which he works is a tertiary referral rheumatology centre within Italy, for the diagnosis and management of patients affected with systemic connective diseases. In addition, he has expertise in the management and follow-up of pregnant patients with systemic rheumatic diseases. Professor Doria has also trained over 35 students in Rheumatology.

*Professor Doria is a member of the Lupus Academy Steering Committee and as Chairman (2020) has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

### **Financial Disclosures**

None

# Biographies



*Professor Dörner is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

## Financial Disclosures

**Grants/Research:** Celgene; Eli Lilly; Janssen; Novartis; Roche; Sanofi-Aventis; UCB

**Consultant/Advisor:** Eli Lilly; Janssen; Novartis; Roche; UCB

## Professor Thomas Dörner, MD Charite University Hospitals Berlin, Germany

Thomas Dörner is a board-certified Rheumatologist and Professor of Rheumatology and Hemostaseology at Charite University Hospitals, Berlin, and group leader at the German Research Center of Rheumatology, Berlin (DRFZ). He qualified in medicine in 1990 at Charite University Hospitals, Berlin, and received his board certification in internal medicine in 1995 before undertaking a postdoctoral fellowship at the University of Texas, Southwestern Medical Center in Dallas, where he researched delineating molecular aspects of B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has received a number of international and national awards, including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, the Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases, Global Arthritis Research Network (GARN), Current Reviews in Rheumatology, the Brazilian Journal of Rheumatology, the European Journal of Immunology, Lupus Science & Medicine, and Rheumatology Reviews.

Professor Dörner has led various clinical trials on rheumatic diseases, including systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue (lupus, neonatal lupus syndromes, Sjogren's syndrome), exploring innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.



## Financial Disclosures

None

## Professor Rebecca Fischer-Betz, MD Heinrich-Heine University, Düsseldorf, Germany

Rebecca Fischer-Betz is the Deputy Head of the Department of Rheumatology at Heinrich-Heine University. She graduated with a degree in Medicine from the Westfalian Wilhelms-University in Münster, Germany, before completing an internship in the Department of Gastroenterology, Endocrinology and Rheumatology. In 1994, Dr Fischer-Betz began a six-year residency in internal medicine in the Department of Nephrology and Rheumatology at Heinrich Heine University in Düsseldorf. In 1999, she attended a programme in clinical effectiveness at the Harvard School of Public Health, USA.

Expanding upon her background in rheumatology, Dr Fischer-Betz's work focuses on fertility and pregnancy in relation to inflammatory rheumatic diseases. She sits on the Board of the German Society of Rheumatology and is Chair of the Pregnancy in Rheumatic Disease Study Group. She is both a member of the EULAR expert group on medications in pregnancy and of the EULAR expert group on women's health and family planning.

Dr Fischer-Betz is leading a long-term, grant-funded research project on pregnancy in rheumatic diseases with a focus on course of pregnancies and safety of new anti-rheumatic drugs. Immunotherapy and immunosuppression as well as different aspects of pregnancy in autoimmune diseases are priority research areas within her work and she has contributed to over 80 publications in this field.

Dr Fischer-Betz has run a pregnancy clinic at the Department of Rheumatology for more than 20 years and offers pre-pregnancy counselling.





## Professor Richard Furie

Zucker School of Medicine at Hofstra/Northwell, New York, USA

Professor Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System's clinical research program in musculoskeletal disease. He also directs the Hospital's systemic lupus erythematosus (SLE) and Autoimmune Disease Treatment Center, which has become internationally recognised for its role in the development of new therapies for SLE.

Regarded as one of the senior rheumatologists in the New York metropolitan area, Professor Furie has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For twenty years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Professor Furie's favourite educational venue is at home with his colleagues and trainees.

*Professor Furie is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

### Financial Disclosures

**Grants/Research:** Biogen;  
BMS; Genentech/Roche;  
Kezar; UCB

**Consultant/Advisor:** Biogen;  
BMS; Genentech/Roche;  
Kezar; UCB



## Professor Bevra Hahn, MD

University of California, Los Angeles, USA

Bevra Hahn is Distinguished Professor of Medicine (Emeritus, recalled for part-time work) in the Division of Rheumatology at the University of California, Los Angeles (UCLA). She received her medical degree and Rheumatology training at Johns Hopkins University School of Medicine in Baltimore, Maryland. She was Chief of Rheumatology at UCLA for 30 years.

Professor Hahn has published research in clinical investigations and basic studies of immune tolerance (including the invention of a tolerizing peptide) and T-cell biology as they apply to systemic lupus erythematosus (SLE). For these works she and her colleagues have received several awards, including the Carol-Nachman International Award for Rheumatology Research, awards from the British Society for Rheumatology and the Dutch Society for Rheumatology, the James Klinenberg Medal of the US Arthritis Foundation, an award from the Canadian Rheumatism Society, and the Gold Medal of the American College of Rheumatology (ACR). Professor Hahn was President of the ACR (1999–2000). She is co Editor, with Daniel Wallace, of the 'Dubois' Lupus Erythematosus textbook and is first author of the ACR guidelines for the management of lupus nephritis. She continues to work in clinical research devoted to the study of SLE.

*Professor Hahn is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

### Financial Disclosures

**Consultant/Advisor:** Aurinia,  
Cugene



# Biographies



**Dr Sarfaraz Hasni, MS, MD**  
NIAMS & NIH, Bethesda, Maryland, USA

Sarfaraz Hasni is the Director of Lupus Clinical Research and Associate Research Physician at the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) in Bethesda, Maryland, USA. He did his Post-graduate training in Internal Medicine and Rheumatology at the State University of New York and completed a Master of Health Sciences in Clinical Research at Duke University.

Dr Hasni revamped the systemic lupus erythematosus (SLE) Natural History Cohort at the NIH, which led to several novel discoveries in pathogenesis of SLE. He conducted several proof of concept clinical trials based on discoveries primarily made at the NIH.

Dr Hasni is part of the core teaching faculty for the rheumatology fellowship training programme and a mentor of the National Research Mentoring Network (NRMN). He also established a regional network of local practitioners, patients and patient advocacy groups interested in advancing clinical research in SLE called DC Lupus Consortium (DCLC). He is an advisory member of Lupus Research Alliance for COVID vaccines and an American College of Rheumatology designated Expert on Call.

Dr Hasni has presented research at multiple regional, national and international conferences, medical grand rounds and patient summits. He has authored more than 50 publications and book chapters.

**Financial Disclosures**  
None



**Professor Thomas Huizinga, MD, PhD**  
Leiden University Medical Center, The Netherlands

Thomas Huizinga is Chairman of Rheumatology at Leiden University Medical Center, The Netherlands.

Professor Huizinga studied medicine at the University of Amsterdam and obtained his degree in 1986. He received his PhD in Medical Sciences cum laude in 1989 and trained as a rheumatologist at Leiden University from 1991–1997. Professor Huizinga has worked as a rheumatologist at Leiden University Medical Center since 1997, he became a full professor in 2000 and Chairman of the Department of Rheumatology in 2006.

Professor Huizinga was awarded the Carol-Nachman award in 2018. His rheumatology department has been recognized as Center of Excellence in Rheumatology and he has been involved in numerous research projects and clinical trials. These achievements are reflected in >80 finished PhD projects, >800 peer reviewed articles and a H. factor of >100. The Department of Rheumatology at Leiden University has ranked highest in the world (<http://cwur.org/2017/subjects.php#Rheumatology>).

Professor Huizinga's expertise is in translational and clinical rheumatology with a strong focus on pathogenesis. He has been involved in the discovery of the relevance of the anti-citrullinated peptide autoantibody responses for diagnoses and development of rheumatoid arthritis (RA). Moreover, his team has discovered a new family of autoantibodies in RA, the anti-carbamylated autoantibodies in autoimmune disease.

Within the field of systemic lupus erythematosus (SLE) Professor Huizinga's team founded a national referral center for Neuro-Psychiatric manifestations of SLE and have published more than 60 scientific publications on this topic during the last 20 years.

**Financial Disclosures**  
None



## **Professor David Isenberg, MD, FRCP, FA MS** University College London, UK

*Professor Isenberg is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

### **Financial Disclosures**

#### **Consultant/Advisor:**

AstraZeneca; Amgen; Idorsia; MerckSerono; Servier

David Isenberg is the Arthritis Research UK Diamond Jubilee Professor of Rheumatology at University College London (UCL). He graduated from St. Bartholomew's Hospital, London, in 1973, and trained in general medicine, rheumatology, neurology, psychiatry and gastroenterology, becoming a Research Fellow at UCL/The Middlesex Hospital in 1979. He was awarded his MD in 1984, based on his studies of myositis. During a year of research at Tufts University, Boston, he became interested in autoantibody structure/function and origin. He was appointed Consultant Rheumatologist in 1984, Professor in 1991 and became the arc Diamond Jubilee Chair of Rheumatology at UCL in 1996. He has fellowships of both the Royal College of Physicians and the Academy of Medical Sciences.

Professor Isenberg is on the Editorial Boards of five journals, including the Journal of Rheumatology. He is Chair of the British Isles Lupus Assessment Group and Lupus UK's Research Committee and was Chair of the Systemic Lupus International Collaborating Clinics group (1998–2003). During the past 20 years, Professor Isenberg has undertaken many roles at Arthritis Research UK and currently sits on the Executive Board.

Professor Isenberg is past-President of the British Society for Rheumatology (2004–2006) and he chaired the Society's Biologics Register Committee for 5 years (2006–2011). Professor Isenberg was the 2010 recipient of the Evelyn V. Hess Prize from the Lupus Foundation of America for his contribution to lupus research and treatment. He has authored over 550 original articles, 275 reviews/chapters and 20 books, many on topics related to lupus.

Professor Isenberg's principal clinical interests are the development of disease activity and damage assessment tools in patients with lupus. His specialist interest is autoimmune rheumatic diseases, notably systemic lupus erythematosus, Sjogren's syndrome, myositis and antiphospholipid antibody syndrome. In 2016 he became a Master of the American College of Rheumatology.



## **Professor David Jayne, MD** University of Cambridge, UK

David Jayne is Professor of Clinical Autoimmunity at the University of Cambridge, UK, and Director of the Vasculitis and Lupus service at Addenbrookes Hospital Cambridge. He trained at the Universities of Cambridge and London, and in nephrology at Harvard Medical School, Boston, USA. He was a research fellow at Imperial College London and the University of Cambridge and was appointed as a Senior Lecturer in Nephrology at St George's Hospital London. Since 2001 he has been working in Cambridge where he is an Honorary Consultant Physician at Addenbrookes Hospital.

Professor Jayne's research has focused on ANCA associated vasculitis and on the development of clinical trials to optimise current therapies and introduce new agents. Topics have included intravenous immunoglobulin, plasma exchange, mycophenolate mofetil and several newer immunosuppressives including rituximab. In parallel, he has investigated newer therapies in systemic lupus erythematosus (SLE) and lupus nephritis, including stem cell transplantation, mycophenolate mofetil and rituximab and has been an advisor on many pharma sponsored clinical trials. Most recently he has been working with Aurinia Pharmaceuticals on the development of voclosporin and with Chemocentryx on the development of avacopan.

Professor Jayne is a co-founder and the current President of the European Vasculitis Society that has led a sequence of International randomised controlled trials over the last 25 years. Initially, in Europe, these have recently included networks in North America, Japan and Australia/New Zealand and have established evidence for the current standards of care in vasculitis. He has published over 500 peer reviewed papers and has chaired or contributed to numerous guideline statements including the EULAR-ERA task force on lupus nephritis and KDIGO guidelines for glomerulonephritis. The Vasculitis and Lupus service in Cambridge cares for over 2000 patients with complex multi-system autoimmunity from the Eastern region of England and further afield. This has provided a background on which to influence the development of care networks for these diseases in the UK.

### **Financial Disclosures**

#### **Grants/Research:**

Chemocentryx

#### **Consultant/Advisor:**

Chemocentryx; GSK; Roche; Vifor Pharma

# Biographies



**Professor Annegret Kuhn, MD, MBA**

University of Muenster / Hospital Passau, Germany

Annegret Kuhn is Professor (adj.) of Dermatology and Venereology at the University of Muenster and Medical Director, CEO, of the Hospital Passau, Germany.

Professor Kuhn received her qualification in Dermatology and Venereology at the University of Duesseldorf, Germany, where she also acquired her Doctor of Medicine and her qualification as University Lecturer. She held a Heisenberg-Scholarship from the German Research Foundation (DFG) between 2005 and 2009 worked in University departments and scientific institutions, such as the Max-Planck-Institute for Molecular Biomedicine, Muenster, and the German Cancer Research Center, Heidelberg, Germany.

Professor Kuhn's major clinical and scientific interest is translational immunology, with particular interest in the pathogenesis, diagnosis, and treatment of skin manifestations in lupus erythematosus. She has also acquired extensive knowledge in all areas of Dermatology and Venereology and has gained long-term experience in academic care of in- and out-patients with autoimmune diseases.

Professor Kuhn is Chair of national and international guideline committees and is working on new diagnostic and therapeutic strategies for cutaneous lupus erythematosus. She was Chair of the European Society of Cutaneous Lupus Erythematosus (EUSCLE) between 2004 and 2017 and is member of several German and international medical societies, and reviewer of several clinical and scientific peer reviewed journals. Professor Kuhn has published widely in high impact journals, including more than 150 original and review articles.

## Financial Disclosures

**Grants/Research:** LEO

Pharma AG

**Consultant/Advisor:** Bayer;

Lilly Deutschland AG

**Speakers' Bureaux:** Bristol-

Myers Squibb GmbH & Co

KGaA; Janssen Cilag AG



## Professor Liz Lightstone, PhD, FRCP Imperial College London, UK

### Financial Disclosures

**Consultant/Advisor:** Achillion;  
Alexion; Astra Zeneca; Aurinia;  
BMS; GSK; Janssen; Pfizer  
**Meeting Honorarium/**  
**Expenses:** Achillion; Alexion;  
GSK

Liz Lightstone is Professor of Renal Medicine in the Centre for Inflammatory Disease, Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, College Consul (Clinical) for Imperial College and an Honorary Consultant Renal Physician in the Imperial College Healthcare NHS Trust Renal and Transplant Centre (ICHNT RTC). After graduating with a first-class degree in Medical Sciences Tripos from Cambridge University, she graduated medicine with honours (*proxime accessit*) from the University of London in 1983 and trained in nephrology at the Royal Postgraduate Medical School and Hammersmith Hospital. Following a PhD in Immunology funded by the Medical Research Council (MRC), she won an MRC Clinician Scientist Fellowship following which she was appointed as Senior Lecturer at Imperial College London in 1995.

Professor Lightstone has held major roles in undergraduate and postgraduate medicine at Imperial College, and more recently she has been appointed Deputy Campus Director Hammersmith White City Campus and elected to the role of Faculty of Medicine College Consul (Clinical).

Having started out in basic research, Prof Lightstone's research is now focused on Lupus Nephritis, as well as Pregnancy in Women with Kidney Disease. Together with colleagues in the Imperial College Healthcare NHS Trust Renal and Transplant Centre, she pioneered the use of steroid-minimising regimens in lupus nephritis. She was Chief Investigator on the international multicentre randomised RITUXILUP trial. She is particularly interested in developing better ways of predicting outcomes, not least by improving adherence to therapy and using an 'omics approach to analyzing renal biopsies. She is a co-author on the EULAR guideline on the management of Lupus Nephritis (2012) and the more recent British Society of Rheumatology guideline on the management of lupus in adults (2017). She is the UK CI on two current RCTs in LN and local PI on another.

She is also recognized for her wider expertise in glomerulonephritis and is now the global co-Chair, along with Prof Dan Cattran, of the Standardised Outcomes in Nephrology-Glomerulonephritis (SONG-GN) initiative which aims to define core outcome criteria to be included in all studies of GN – and these outcomes are generated and evaluated by both healthcare professionals and patients. She also co-Chairs, with Professor David Jayne, the UK Kidney Research Consortium Glomerulonephritis Clinical Study.

She was the inaugural National Coordinator of the UK Pregnancy and Chronic Kidney Disease Rare Disease group and pioneered the use of tacrolimus in the treatment of lupus nephritis in pregnancy and demonstrated its safety for women with lupus nephritis who are breastfeeding. She is joint author on the first Renal Association Guideline on the Pregnancy and Chronic Kidney Disease published in 2019 and has published extensively on the management and outcomes of pregnancy in women with glomerular disease, in particular lupus nephritis.

Her main clinical interests are in lupus nephritis (she jointly manages a combined renal/rheumatology lupus clinic following over 400 patients with LN) and the management of women with kidney disease in pregnancy—she established (in 1996) and runs a renal obstetric clinic and a pre-pregnancy counselling clinic & her advice is sought nationally and internationally for the management of challenging cases in these areas.



# Biographies



**Professor Eric Morand**, MBBS (Hons), FRACP, PhD  
Monash University, Melbourne, Australia

Eric Morand is Professor of Medicine and Head of the School of Clinical Sciences at Monash University, and Head of Rheumatology at Monash Health, in Melbourne, Australia.

He trained in rheumatology in Australia and at the Royal National Hospital for Rheumatic Diseases, UK, before completing his PhD at Monash University where he has lead rheumatology research since. He is a member of and former board member of the Australian Rheumatology Association, and an International Fellow of the American College of Rheumatology.

His laboratory research program focuses on the effects of glucocorticoid-induced proteins in the immune system, with the overarching goal of finding pathways to deliver glucocorticoid-mimicking therapeutic effects without adverse effects. This led to the description of the expression and function of four novel proteins in rheumatic disease tissues and models. Recent work on glucocorticoid-induced leucine zipper (GILZ) led to the William E Paul Distinguished Innovator Award of the Lupus Research Alliance, New York, in 2015.

His clinical research focuses on systemic lupus erythematosus (SLE), with a strong emphasis on improving measurement and understanding the drivers of adverse outcomes. He founded the Lupus Clinic at Monash Health, now Australia's largest lupus cohort and biobank, which led to the formation of the Australian Lupus Registry and Biobank, a national multicenter registry. He founded and chairs the Asia Pacific Lupus Collaboration, now among the largest longitudinal cohorts of SLE patients ever assembled, with over 3,300 patients under longitudinal follow-up. This group developed and prospectively validated the Lupus Low Disease Activity State (LLDAS) measure for treat-to-target studies in SLE, which has since been validated as a potential clinical trial endpoint.

Professor Morand is an advisor on lupus measurement and trials to multiple pharma and biotech companies. He was Principal Investigator of the TULIP-2 Phase 3 trial of anifrolumab, the second ever targeted therapy with a positive Phase 3 trial in lupus, currently under regulatory review worldwide.

He chaired the 2017 International Congress on SLE and is on the editorial boards of *Nature Reviews Rheumatology*, *The Lancet Rheumatology*, and *Lupus Science & Medicine*. Professor Morand's outputs include over 250 publications, book chapters, and patents, which have been cited >12,000 times.

## Financial Disclosures

### Grants/Research:

AstraZeneca; Bristol Myers Squibb; Eli-Lilly; Jansen

### Consultant/Advisor:

Amgen; AstraZeneca; Biogen; Bristol Myers Squibb; Eli-Lilly; Jansen

### Speakers' Bureaux:

Amgen; AstraZeneca; Biogen; Bristol Myers Squibb; Eli-Lilly; Jansen



**Professor Sandra Navarra**, MD  
University of Santo Tomas, Manila, Philippines

Sandra Navarra is Professor and Head of Rheumatology at University of Santo Tomas Hospital, Manila, Philippines. She served as Secretary-General, head of the Education Committee, chaired the special interest group on systemic lupus erythematosus (SLE) of the Asia Pacific League of Associations for Rheumatology (APLAR), and was past-President of the Philippine Rheumatology Association.

Professor Navarra co-founded the Arthritis Care and Research Foundation of the Philippines, where she was Scientific Programs Director, and the Lupus Foundation of the Philippines where she has served as Medical Adviser. Currently President and CEO of the Rheumatology Educational Trust Foundation Inc. (RETFI), she is the prime mover of the Lupus Inspired Advocacy (LUIA) Project for lupus education and research, and the People Empowerment for Arthritis and Lupus (PEARL) Movement for lay education and medical assistance programs. Professor Navarra is a member of the Lupus Academy Steering Committee, and a founding and executive board member of both Asia Pacific Lupus Collaboration (APLC) and Asian Lupus Nephritis Network (ALNN).


Professor Navarra is an experienced clinical trials investigator and has published widely in the field of lupus and other rheumatic diseases. She is a well-known lecturer in a broad range of topics in Rheumatology and has received several university and national awards for her contributions to education and research. She has organized several national and regional educational meetings including the Ten Topics in Rheumatology – Asia (November 2009), first Asian Lupus Summit (November 2012), Asian Lupus Summit by Lupus Academy (March 2014), Lupus Nephritis Forum (July 2015), Lupus Academy Roadshow Meetings (May 2016, November 2017, May 2018), Musculoskeletal Imaging for Clinicians and Lupus for the Internist (May 2019) – all held in the Philippines.

*Professor Navarra is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

## Financial Disclosures

None





**Dr Marc Pineton de Chambrun, MD**  
**La Pitié-Salpêtrière Hospital, Paris, France**

Marc Pineton de Chambrun is an internist and intensivist working at La Pitié-Salpêtrière Hospital, Paris, France.

Dr Pineton de Chambrun received his Medical Degree and qualification in Internal Medicine in 2016 and his qualification in Intensive Care Medicine in 2020 from the Sorbonne University and La Pitié-Salpêtrière University Hospital. Between 2016 and 2019, during his first fellowship, he was trained on the management of connective tissue diseases, especially systemic lupus erythematosus and antiphospholipid syndrome by Professor Zahir Amoura.

Since 2019, he has worked in the ECMO-dedicated Intensive Care Medicine department of Professor Alain Combes, under whose direction he is currently undertaking a PhD on the outcome of critically-ill patients with rare immunological diseases. Being at the confluence of two medical specialties, he has developed an expertise on the management of severe systemic rheumatic diseases patients and has authored over 50 ISI publications. His area of expertise includes among other conditions Clarkson's Disease and Catastrophic Antiphospholipid Syndrome.

**Financial Disclosures**

None



**Professor Bernardo Pons-Estel, MD**  
**Regional Center for Autoimmune and Rheumatic Diseases and the Cardiovascular Institute of Rosario, Argentina**

Bernardo Pons-Estel is Head of the Regional Center for Autoimmune and Rheumatic Diseases (CREAR), and the Cardiovascular Institute of Rosario (ICR), Argentina. He received his medical degree from the National University of Rosario and went on to train in rheumatology, first in Argentina (Rosario) and thereafter the USA, where he was a fellow at New York University (Bellevue Hospital and the Irvington House Institute, New York) and at the University of Missouri Cancer Research Center, Columbia.

Professor Pons-Estel is the main coordinator for the Latin American Group for the Study of Systemic Lupus Erythematosus (GLADEL), the Genomic Study of Latin-American Patients with SLE (GLA-GENLES) and the Latin American Group for the Study of Rheumatic Diseases in Indigenous People (GLADERPO). He is past-President of the Argentinean Rheumatology Society (2011–2013). In 2013, he chaired the 10th International Congress on SLE, which took place under GLADEL sponsorship in Buenos Aires, Argentina and in 2018 he chaired the Pan-American League of Rheumatology Associations (PANLAR) Congress in Buenos Aires.

Professor Pons-Estel is a council member of the Science and Educational Committee of the Pan-American League of Association for Rheumatology (PANLAR). He is also an active member of the Systemic Lupus International Collaborating Clinics (SLICC), member of the Lupus Academy Steering Committee and an International Member of the ACR. Recently, a collaboration between GLADEL and PANLAR materialised, the aim being the development of guidelines for the management of SLE patients from the Latin American subcontinent; Bernardo is an integral part of this collaboration.

*Professor Pons Estel is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

**Financial Disclosures**

**Grants/Research:** Jansen  
**Consultant/Advisor:** GSK

# Biographies



## Professor Jane Salmon, MD

Weill Cornell Medical College, New York, USA

Jane Salmon is the Collette Kean Research Professor and Director of the Lupus and Antiphospholipid Center of Excellence at Hospital for Special Surgery. She is Professor of Medicine and Associate Dean, Faculty Affairs at Weill Cornell Medicine.

Professor Salmon earned her medical degree from the Vagelos College of Physicians and Surgeons of Columbia University and trained in rheumatology at Hospital for Special Surgery.

Professor Salmon's research has focused on elucidating mechanisms of tissue injury in lupus and other autoimmune diseases. Her basic, translational and clinical studies have led to a paradigm shift in the understanding of mechanisms of pregnancy loss, cardiovascular disease and end-organ damage in lupus. Ground-breaking laboratory discoveries about causes of pregnancy loss and preeclampsia, and subsequent observational studies in women with lupus have allowed her to identify new targets to reduce damage and improve outcomes in patients with autoimmune illness.

In recognition of her contributions, she was awarded the Carol Nachman international prize in rheumatology, the Virginia Kneeland Frantz '22 Distinguished Women in Medicine Award from the Columbia P&S Alumni Association, the Evelyn V. Hess Award from the Lupus Foundation of America and election to the American Association of Physicians and the National Academy of Medicine.

### Financial Disclosures

Grants/Research: UCB

Consultant/Advisor: UCB



## Professor Lisa Sammaritano, MD

Weill Cornell Medical College, New York, USA

Lisa Sammaritano is Professor of Clinical Medicine at Weill Cornell Medicine and an Attending Physician at Hospital for Special Surgery.

Professor Sammaritano completed medical school, residency, and rheumatology fellowship training at Weill Cornell Medicine. Her clinical and research interests include systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and reproductive issues in rheumatic disease patients. In addition to her clinical practice, she has participated in a number of large clinical trials including the SELENA studies, prospective randomized double-blind studies of safety of oestrogen in SLE patients, and the PROMISSE study, an observational study of pregnancy risk in patients with SLE and aPL.

Professor Sammaritano has written numerous review articles and chapters, edited a textbook on contraception and pregnancy in rheumatic disease patients (2014) and lectures nationally and internationally. Most recently, she was the primary investigator and lead author for the American College of Rheumatology Guideline project on reproductive health in rheumatic disease patients (2020). She conducts reproductive health studies in rheumatic disease patients in collaboration with her colleagues in the Rheumatology Reproductive Health Program of the Barbara Volcker Center at the Hospital for Special Surgery, which focuses on research, clinical care, and fellow and resident education.

### Financial Disclosures

None




**Dr Y.K.O. (Onno) Teng, MD, PhD**  
Leiden University Medical Center, The Netherlands

Onno Teng is a Nephrology clinician-scientist at the department of Internal Medicine of the Leiden University Medical Center (LUMC). He is head of the Nephrology outpatient clinic and coordinator of the Leiden outpatient clinic for Lupus, Vasculitis and Complement-mediated Systemic diseases (LuVaCs) which accommodates top-referral, multidisciplinary, tertiary care on a regional and national level. He also leads and coordinates a clinical, multidisciplinary pathway aimed at counselling and guiding a pregnancy wish of patients with systemic lupus erythematosus (SLE) or antiphospholipid syndrome.

Dr Teng conducts a translational research program in the area of autoimmune glomerulonephritis related to systemic lupus erythematosus (SLE) and ANCA-associated vasculitis (AAV). His major goals are to find new therapeutic interventions and innovative approaches for immunological monitoring ('immunomonitoring') for patients with SLE and AAV. His research activities are therefore divided in two main areas: 'novel treatment strategies' and 'innovative immunomonitoring'. Both areas are closely related because the search for novel treatment options in SLE and AAV almost simultaneously requires the need for new immunomonitoring tools. Immunomonitoring in SLE and AAV patients helps us to better understand a) the underpinning immunological pathophysiology and b) the beneficial effects of novel treatments on autoimmunity. In addition, immunomonitoring can potentially help doctors and patients when choosing a personalised treatment strategy, to define response to treatment on a clinical as well as an immunological level and to predict prognosis of the disease.

**Financial Disclosures**

**Grants/Research:** Aurinia Pharmaceuticals; GSK  
**Consultant/Advisor:** Aurinia Pharmaceuticals; GSK; KezarBio; Novartis



**Professor Murray Urowitz, MD**  
University of Toronto, Canada

Murray Urowitz is a senior staff rheumatologist at the Toronto Western Hospital and Senior Scientist at the Krembil Research Institute and Schroeder Arthritis Institute. He is currently Professor of Medicine at the University of Toronto and Director of the Centre for Prognosis Studies in the Rheumatic Diseases and the Lupus Clinic at the Toronto Western Hospital.

Professor Urowitz was a founding member of the Systemic Lupus International Collaborating Clinics (SLICC) group and currently directs the SLICC Registry for Atherosclerosis. In 1995 he was the recipient of the Distinguished Rheumatologist Award of the Canadian Rheumatology Association and in 2009 he was recipient of the Evelyn V. HESS Award for outstanding contributions to lupus research, awarded by the Lupus Foundation of America. He was the recipient of the Queen Elizabeth Diamond Jubilee Medal for longstanding contributions to lupus research work in the field of rheumatology in 2015. In 2017 he was awarded the Distinguished Clinical Investigator Award for exceptional contributions to the field of rheumatology by the American College of Rheumatology. In May 2019 was the recipient of the University of Toronto Dean's Alumni Lifetime Achievement Award for Global Impact.

Professor Urowitz has published 447 peer-reviewed papers and 46 book chapters. He has supervised the training of over 140 fellows in rheumatology especially in systemic lupus erythematosus.

*Professor Urowitz is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting programme and materials.*

**Financial Disclosures**

**Advisory Boards:** AZ, GSK, UCB  
**Data Safety Monitoring Committees:** Syneos, UCB  
**Research Support:** GSK

# Biographies



## Professor Ronald van Vollenhoven, MD, PhD

**Amsterdam University Medical Centers, and Amsterdam Rheumatology & Immunology Center, Netherlands**

Professor Ronald van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology and Immunology Center ARC in Amsterdam, the Netherlands.

He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by residency (specialty training) in Internal Medicine at the State University of New York at Stony Brook, and at Stanford University, leading to an American Board of Internal Medicine certification in both Internal Medicine and Rheumatology.

From 1993 to 1998 Professor van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division. In 1998 he moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; in 2010, he was appointed as Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute.

In January 2016 Professor Vollenhoven was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and Chair of Rheumatology at both the AMC and VUMC hospitals, which in 2018 merged into the Department of Rheumatology and Clinical Immunology of the new Amsterdam UMC. He is also the Director of the Amsterdam Rheumatology and Immunology Center I, and Chair of the Rheumatology Research Council at Reade in Amsterdam, all located in Amsterdam. Professor van Vollenhoven's research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database), which supported research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoeconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT, ADMIRE, and DOSERA trials. He has published over 400 original papers (H-index: 75), book chapters and reviews, and is associate-editor of Dubois' Lupus Erythematosus (Elsevier, 2014), editor of the textbook Clinical Therapy Research in the Inflammatory Diseases (World Scientific Press, 2015), author of the monograph Biological Therapy of Rheumatoid Arthritis (Springer, 2015) and co-author, with Professor Laurent Arnaud, of the Handbook of Systemic Lupus Erythematosus (Springer, 2017). In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, and he is an honorary member of several rheumatological societies, and in 2019 he was awarded the Dutch Rheumatology Society's highest award, the Jan van Breemen medal. He is the Editor-in-Chief of Lupus Science & Medicine, Member-elect of the EULAR Executive, past-Chair of the Swedish Rheumatology Society Professors' Council, co-founder of the IRBIS registry for biologics in SLE, the CERERRA registries collaboration and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE and DORIS initiatives.

Professor van Vollenhoven is married and has two children aged 25 and 21. Outside his professional life he is an avid classical pianist.

### Financial Disclosures

**Grants/Research:** BMS; GSK; Lilly; Pfizer; Roche; UCB

**Consultant/Advisor:** AbbVie; AstraZeneca; Biogen; Biotest; BMS; Galapagos; Gilead; GSK; Janssen; Pfizer; Sanofi; Servier; UCB; Vielabio

**Speaker, for which institutional and/or personal honoraria were received:**

AbbVie; Galapagos; Janssen; Pfizer; UCB

Professor van Vollenhoven is a member of the Lupus Academy Steering Committee and as Chairman (2020) has been involved in the planning and development of the 10th Annual Meeting programme and materials.





**Denis Wahl, MD, PhD**  
University of Lorraine, Nancy France

**Financial Disclosures**  
None

Denis Wahl is Professor of Vascular Medicine at the University of Lorraine, Nancy, France. He has been involved in antiphospholipid syndrome (APS research) for more than 25 years, with funding from Nancy University, Nancy University Hospital, Programme Hospitalier de Recherche Clinique – French ministry of Health, Fondation de France and INSERM. He and his colleagues formed an Antiphospholipid Antibodies Investigator network in France for the TACT-TACIT and subsequent studies in 2004 and from then on.

Professor Wahl participated in the workshop that established the International consensus statement on an update of the classification criteria for definite APS in 2004 in Sydney (criteria published in 2006). He is currently working with Dr Erkan (ACR primary investigator, USA) and Dr Zuily (EULAR primary investigator, France) on the ACR/EULAR criteria task force for APS. Professor Wahl has also been on the National Advisory Committee of the International aPL Symposium in Tours in 2000 and has been a member of the International Advisory Committee of the International aPL congresses since 2013. He is currently planning the next congress in Cordoba (Argentina) in 2022.

Professor Wahl has participated in the APS ACTION international clinical research working group from its start in 2010. He has many years of experience of studies on antiphospholipid antibodies and several studies are underway at his centre. Professor Wahl has participated in most European Forum meetings and has been the General Coordinator of the European Forum on antiphospholipid antibodies since 2018.



**Professor Sacha Zeerleder, MD PhD**  
University Hospital of Bern, Switzerland

**Financial Disclosures**

Grants/Research: Jazz  
Pharma; Shire  
Consultant/Advisor: Jazz  
Pharma; Sanofi; Shire; Takeda

Sacha Sergio Zeerleder received his MD from the University of Berne (Switzerland) in 1997. He completed his training as internist hematologist at the University hospital Bern, Switzerland, and at the Academic Medical Center (AMC) in Amsterdam, the Netherlands.

From 2010 to July 2018 Professor Zeerleder worked as staff hematologist at the Academic Medical Centre AMC and as principle investigator at Sanquin Research in Amsterdam. At the AMC, he was the Director of the stem cell transplantation programme, medical head of the special hematology laboratory and the transfusion laboratory. In 2016, he was appointed full professor for Immunohematology at the University of Amsterdam. Since August 2018 has been Chief Physician at the University Hospital (Inselspital) in Bern (Switzerland) and is responsible for the transfusion service, apheresis unit, he is also Director of the programme of cellular therapies and Vice Director of the Hematooncology Center at the University Cancer Center Inselspital (UCI). In July 2019, he received the “*Venia docendi*” and his “Associate Professorship” at the medical faculty at the University of Bern.

Professor Sacha Zeerleder’s research is dedicated to the role of innate immunity, with a special focus on damage-associated molecular pattern (DAMPs) in the pathophysiology of hematological diseases.





# About the Lupus Academy

## Mission

The Lupus Academy is a not-for-profit, long-term initiative committed to improving patient outcomes in SLE and allied diseases. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research.

## Meeting Organisation

The 10th Annual Meeting of the Lupus Academy has been developed under the control of the meeting Chairs: Professor Zahir Amoura (France) and Professor Richard Furie (USA), on behalf of the Steering Committee of the Lupus Academy, and with the support of the planning staff at Lupus Academy. It has been developed in Joint Providership with Siyemi Learning, an ACCME-accredited provider for CME compliance and certification. No other individuals or organisations have had any influence over the content of this meeting.

## Other Educational Activities

The Lupus Academy runs an Annual Meeting and several regional Roadshow Meetings each year. It also has an extensive library of presentations that is available to registered members, currently free of charge. The Lupus Academy is also developing a series of eLearning activities to support its educational goals. From 2019 Lupus Academy has been proud to be the provider of the eLearning course on SLE for the European League Against Rheumatism (EULAR).

More information about all Lupus Academy educational activities can be found at [lupus-academy.org](https://lupus-academy.org).

## Further Information

The Lupus Academy is a not-for-profit educational foundation with its office in the Netherlands, RSIN 851342097.

Lupus Academy Foundation  
Maasdijk 409  
4264 AS Veen  
The Netherlands

## Supporters



**Financial Supporters**

INDEPENDENT EDUCATIONAL GRANT  
**GSK, BMS, Aurinia**

GOLD SPONSOR  
**Janssen**

BRONZE SPONSOR  
**AstraZeneca, Galapagos, Lilly, Novartis, UCB**

ACADEMY PARTNERS  
**Amgen, Bayer, Biogen, BMS**

FRIEND OF THE ACADEMY  
**Servier**

## In-kind Supporters



Financial and in-kind support is only accepted on a strictly “hands-off” basis, where the supporting companies do not have any control or influence over the planning, content, speaker selection or execution of educational activities. Support is received as educational grants, sponsorship, donations or in-kind, and where used, clearly identified.





